Raoel Maan

1.4k total citations
34 papers, 737 citations indexed

About

Raoel Maan is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Raoel Maan has authored 34 papers receiving a total of 737 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Hepatology, 24 papers in Epidemiology and 5 papers in Surgery. Recurrent topics in Raoel Maan's work include Hepatitis C virus research (26 papers), Liver Disease Diagnosis and Treatment (22 papers) and Liver Disease and Transplantation (16 papers). Raoel Maan is often cited by papers focused on Hepatitis C virus research (26 papers), Liver Disease Diagnosis and Treatment (22 papers) and Liver Disease and Transplantation (16 papers). Raoel Maan collaborates with scholars based in Netherlands, Canada and Germany. Raoel Maan's co-authors include Robert J. de Knegt, Jordan J. Feld, Rozanne C. de Veer, Bettina E. Hansen, Harry L.A. Janssen, Michael P. Manns, Heiner Wedemeyer, Bart J. Veldt, Harry L.A. Janssen and Stefan Zeuzem and has published in prestigious journals such as PLoS ONE, Hepatology and Clinical Infectious Diseases.

In The Last Decade

Raoel Maan

32 papers receiving 728 citations

Peers

Countries citing papers authored by Raoel Maan

Since Specialization

Citations

This map shows the geographic impact of Raoel Maan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raoel Maan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raoel Maan more than expected).

Fields of papers citing papers by Raoel Maan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raoel Maan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raoel Maan. The network helps show where Raoel Maan may publish in the future.

Co-authorship network of co-authors of Raoel Maan

This figure shows the co-authorship network connecting the top 25 collaborators of Raoel Maan. A scholar is included among the top collaborators of Raoel Maan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raoel Maan. Raoel Maan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Diabetes Mellitus is a Risk Factor for Hepatic Encephalopathy Following Transjugular Intrahepatic Portosystemic Shunt 2025 ·Alimentary Pharmacology & Therapeutics ·Michelle Spaan, (unknown), (unknown), Nicole S. Erler, (unknown), Sarwa Darwish Murad, Milan J. Sonneveld, Caroline M. den Hoed, (unknown), Dave Sprengers, Willem Pieter Brouwer, Robert J. de Knegt, Harry L.A. Janssen, (unknown), (unknown), Raoel Maan, Rozanne C. de Veer	1
2	Percutaneous Biodegradable Stent Placement for Treatment of Benign Biliary Strictures: A Systematic Review 2025 ·Journal of Vascular and Interventional Radiology ·Amy Chen, (unknown), Roy J.J. Verhage, Raoel Maan, (unknown)	1
3	Antiplatelet Prophylaxis Reduces the Risk of Early Hepatic Artery Thrombosis Following Liver Transplantation in High-Risk Patients 2024 ·Transplant International ·(unknown), Jeroen de Jonge, (unknown), Raoel Maan, Wojciech G. Polak, Robert J. Porte, Harry L.A. Janssen, Bogdan Procopeț, Sarwa Darwish Murad	1
4	Graft Steatosis and Donor Diabetes Mellitus Additively Impact on Recipient Outcomes After Liver Transplantation—A European Registry Study 2024 ·Clinical Transplantation ·Milan J. Sonneveld, (unknown), (unknown), Jeroen de Jonge, Morteza Salarzaei, Robert J. Porte, Harry L.A. Janssen, (unknown), Serge Vogelaar, Rozanne C. de Veer, Raoel Maan, Sarwa Darwish Murad, Wojciech G. Polak, Willem Pieter Brouwer	0
5	Increase in prevalence and costs of cirrhosis in the Netherlands: a nationwide hospital diagnosis data analysis 2024 ·European Journal of Gastroenterology & Hepatology ·Koos de Wit, (unknown), Gwen Masclee, Minneke J. Coenraad, (unknown), Frans J.C. Cuperus, Matthijs Kramer, Raoel Maan, (unknown), Marten A. Lantinga, (unknown)	0
6	Progression of the FIB-4 index among patients with chronic HCV infection and early liver disease 2023 ·BMJ Open Gastroenterology ·(unknown), Raoel Maan, Amy Puenpatom, Nicole S. Erler, Christoph Welsch, Stijn Van Hees, (unknown), Johannes Vermehren, Robert J. de Knegt, Bettina E. Hansen, Stefan Zeuzem, Thomas Vanwolleghem, Harry L.A. Janssen, Robert A. de Man, Jordan J. Feld, Rozanne C. de Veer	1
7	Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity 2020 ·Journal of Hepatology ·(unknown), Raoel Maan, Alnoor Ramji, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer, Robert J. de Knegt, Bettina E. Hansen, Harry L.A. Janssen, Robert A. de Man, Jordan J. Feld, Rozanne C. de Veer	81
8	Ribavirin steady‐state plasma level is a predictor of sustained virological response in hepatitis C–infected patients treated with direct‐acting antivirals 2017 ·Alimentary Pharmacology & Therapeutics ·(unknown), (unknown), Elise J. Smolders, Karel J. van Erpecum, (unknown), Raoel Maan, Marc van der Valk, Joop E. Arends, Anthonius S. M. Dofferhoff, Hans Blokzijl, (unknown), Joost P.H. Drenth, Robert J. de Knegt, David M. Burger, (unknown)	2
9	Interferon-free antiviral therapy for chronic hepatitis C among patients in the liver transplant setting 2017 ·Best Practice & Research Clinical Gastroenterology ·(unknown), Raoel Maan, Rozanne C. de Veer, Robert J. de Knegt	3
10	The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir‐based regimens 2017 ·Alimentary Pharmacology & Therapeutics ·Raoel Maan, (unknown), Jagpal S. Klair, (unknown), Orlando Cerocchi, Matthew Kowgier, (unknown), (unknown), Harry L.A. Janssen, Jordan J. Feld, Andrés Duarte‐Rojo	13
11	Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis 2017 ·Journal of Hepatology ·Suraj Sharma, Matthew Kowgier, Bettina E. Hansen, Willem Pieter Brouwer, Raoel Maan, David Wong, Hemant Shah, Korosh Khalili, Colina Yim, E. Jenny Heathcote, Harry L.A. Janssen, Morris Sherman, Gideon M. Hirschfield, Jordan J. Feld	147
12	Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection 2016 ·Clinical Infectious Diseases ·Johannes Vermehren, Benjamin Maasoumy, Raoel Maan, Gavin Cloherty, (unknown), Jordan J. Feld, Markus Cornberg, Jean–Michel Pawlotsky, Stefan Zeuzem, Michael P. Manns, Christoph Sarrazin, Heiner Wedemeyer	22
13	High Risk of Infection During Triple Therapy with First- Generation Protease Inhibitors: A Nationwide Cohort Study 2016 ·Journal of Gastrointestinal and Liver Diseases ·(unknown), (unknown), Raoel Maan, Robert J. de Knegt, Wietske Kievit, Joost P.H. Drenth	3
14	Real-World Medical Costs of Antiviral Therapy Among Patients With Chronic Hcv Infection and Advanced Hepatic Fibrosis 2015 ·Value in Health ·Raoel Maan, (unknown), Adriaan van der Meer, Jordan J. Feld, Heiner Wedemeyer, Jean‐François Dufour, Frank Lammert, M.P. Manns, Stefan Zeuzem, Bettina E. Hansen, Harry L.A. Janssen, Bart J. Veldt, Robert J. de Knegt, Carin A. Uyl‐de Groot	1
15	Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies 2015 ·Drugs ·Raoel Maan, Robert J. de Knegt, Bart J. Veldt	40
16	ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection 2015 ·PLoS ONE ·Raoel Maan, Rozanne C. de Veer, Willem Pieter Brouwer, Elisabeth P.C. Plompen, Milan J. Sonneveld, (unknown), Annemiek A. van der Eijk, Zwier M. A. Groothuismink, Bettina E. Hansen, Bart J. Veldt, Harry L.A. Janssen, André Boonstra, Robert J. de Knegt	12
17	Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis 2015 ·Journal of Gastroenterology and Hepatology ·Rozanne C. de Veer, Raoel Maan, Bart J. Veldt, Jordan J. Feld, Heiner Wedemeyer, Jean‐François Dufour, Frank Lammert, Andrés Duarte‐Rojo, Michael P. Manns, Stefan Zeuzem, Wolf Peter Hofmann, Robert J. de Knegt, Bettina E. Hansen, Harry L.A. Janssen	40
18	Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients 2014 ·Antiviral Research ·Meike H. van der Ree, Rozanne C. de Veer, Joep de Bruijne, Raoel Maan, André van Vliet, Tania M. Welzel, Stefan Zeuzem, Eric Lawitz, M. Rodríguez‐Torres, Viera Kupčová, Alicja Wiercińska‐Drapało, Michael R. Hodges, Harry L.A. Janssen, Hendrik W. Reesink	145
19	Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis 2014 ·Journal of Hepatology ·Raoel Maan, Rozanne C. de Veer, Bettina E. Hansen, Jordan J. Feld, Heiner Wedemeyer, Jean‐François Dufour, (unknown), Frank Lammert, Michael P. Manns, Stefan Zeuzem, Harry L.A. Janssen, Robert J. de Knegt, Bart J. Veldt	18
20	Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study 2011 ·Journal of Psychopharmacology ·Timothy Roehrs, Sue Randall, Erica Harris, Raoel Maan, Thomas Röth	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact